AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

 AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

Shots:

  • AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) utilizing artificial intelligence (AI) and machine learning
  • AstraZeneca will combine its genomics, chemistry and clinical data with Benevolent AI’s target identification platform and biomedical knowledge graph (network of genes, proteins, diseases and compounds) and will have insights of CKD and IPF diseases for identifying targets
  • Benevolent AI platform is a computational & experimental drug discovery platform which allows findings of pathways to treat disease and personalize drugs to patients focusing on four key areas: knowledge & reasoning, target identification, molecular design and precision medicine

Click here to read full press release/ article | Ref: AstraZeneca | Image: Royal Haskoning

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post